CN1209320A - Medicine - Google Patents
Medicine Download PDFInfo
- Publication number
- CN1209320A CN1209320A CN 97106043 CN97106043A CN1209320A CN 1209320 A CN1209320 A CN 1209320A CN 97106043 CN97106043 CN 97106043 CN 97106043 A CN97106043 A CN 97106043A CN 1209320 A CN1209320 A CN 1209320A
- Authority
- CN
- China
- Prior art keywords
- sulfate
- distilled water
- anhydrous sodium
- glycerol
- sodium sulfite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a spray for curing respiratory tract infection and its preparation method. Its composition includes antibiotic, solvent, assistant and flavouring agent, in which the antibiotic mainly adopts gentamycin sulfate, kanamycin sulfate, micronomicin sulfate, ribostamycin sulfate, sisomicin sulfate and edamycin, etc., the solvent is distilled water; assistant is ethylene glycol, glycerol, ethyl alcohol, dimethyl sulfoxide and span-85, etc, and the flavouring agent is borneol, peppermint oil and other perfume compound. As compared with existent technology, it possesses the advantages of convenient use, less toxic side effect, high curative effect and simple preparation, also can be used for curing the diseases of tonsillitis, rhinitis, laryngitis and skin burn and scald,etc..
Description
The present invention relates to a kind of medicinal aerosol.
Its curative effect of the application of antibiotic medicine depends on the drug level of infection site to a great extent, and the concentration of infection site antibacterials is principal elements of decision clinical efficacy.Think that in theory " target position " administration can improve medicine to predetermined localized selectivity of focus of human body and accuracy, make the drug effect optimization and the whole body toxic and side effects is reduced to minimum degree.
At present, clinically treatment of diseases such as tonsillitis, pharyngitis, laryngitis, acute and chronic tracheitis, bronchitis are extensively adopted antibiotics such as gentamycin, kanamycin, medication mainly is intramuscular injection, and other has the Therapeutic Method of atomizing " target position " administration.But medication mainly sprays into, sucks with aerosol apparatus, high pressure oxygen, high-pressure pump and ultrasonic atomizatio.Its employed medicinal liquid is generally prepared by the medical worker temporarily.The patient need arrive hospital and can receive treatment.
The intramuscular injection whole body administration that as above " target position " route of administration of treatment respiratory tract infection compares is more excellent, and this method can improve the availability of medicine, owing to medicine has reduced its toxic and side effects without systemic circulation.But present medication falls behind, and the patient need run hospital and can receive treatment under medical personnel's help.This had both increased medical personnel's labor intensity, had wasted patient or patient monitoring person's time again.
I was a purpose with toxic and side effects and the convenient popular Heal Thyself that improves drug utilization degree, reduction medicine once, disclosed a kind of antibiotics aerosol preparations and compound method.Along with the development of technology, the micro-sprayer manufacturing technology occurs, and the problem of the propellant in the aerosol preparations can be resolved like this.Utilize micro-sprayer to make the medical atomizing agent, both can simplify preparation technology, save equipment investment, can avoid the destruction of propellant freon again atmospheric ozone layer.The purpose of target administration also can reach simultaneously.
The invention discloses a kind of antibiotics spray novel form and compound method thereof.Antibiotics spray novel formulation comprises principal agent, solvent, antioxidant, auxiliary agent and micro-sprayer composition.
Preparation of the present invention, be after to the physicochemical characteristics of each antibiotics, biological nature comparative study, preferred chemical property is stable, the aminoglycosides antibiotics that does not have irritated reaction and have a powerful bactericidal action is a principal agent, and this class antibiotic comprises kanamycin, gentamycin, micronomicin, ribostamycin, Sissomicin and amikacin, tobramycin, Astromicin, spectinomycin, dibekacin, isepamicin, netilmicin, love rice star (89-07) etc.
The solvent of preparation principal agent of the present invention is a distilled water, can contain other adjuvant in addition.Comprise various suitable flavoring agents.As spice of ethanol, ethylene glycol, glycerol and different flavor etc.
The preparation method of preparation of the present invention is after antimicrobial drug, solvent, auxiliary agent, flavoring agent are prepared in proportion, divides in the cylindrical container of packing into, and encapsulating upward again, the mini spray head gets final product.The micro-sprayer nozzle can be by the different suitably lengthenings in clinical use position.
The used antimicrobial drug of the present invention is the sulfate of said medicine, as gentamycin sulfate, kanamycin sulfate, Micronomicin Sulfate, Vistamycin, Baymicin and other antibiotics is principal agent, with the distilled water is solvent, with glycerol, ethylene glycol, ethanol, dimethyl sulfoxide and Arlacel-85 etc. is auxiliary agent, with Borneolum Syntheticum, Herba Menthae wet goods is flavoring agent, is antioxidant with anhydrous sodium sulfite, sodium pyrosulfate; Its cooperation ratio is: 0.5-20: 5-99: 1-50: 0.001-1.5: 0.3.
Preparation of the present invention is fit to the acute and chronic respiratory tract infection of treatment.As: tonsillitis, diseases such as rhinitis, pharyngitis, laryngitis, tracheobronchitis.Preparation of the present invention also can be used for prophylactic treatment.In addition, preparation of the present invention also can be used for the treatment of skin burn, scald and trauma infection contamination.As for dosage and frequency, will depend on patient's the state of an illness and the age.This can be by the clinicist according to the clinical symptoms final decision.
Preparation of the present invention is that example illustrates its implementation method with single-dose things such as gentamycins.Certainly, principal agent can be the mixture of any of above-mentioned principal agent or itself and other said medicine, and it is good and do not have anaphylactoid other drug or Chinese herbal medicine is made compound preparation also can to add other adequate stability in addition.
Embodiment prescription weight of material percentage ratio (%) (1) gentamycin sulfate 0.5-16
Ethylene glycol 5-50
Anhydrous sodium sulfite 0.3
Distilled water 50-95 (2) gentamycin sulfate 0.5-16
Ethanol 5-50
Distilled water 10-95
Oleum menthae 0.001-0.1
Anhydrous sodium sulfite 0.3 (3) gentamycin sulfate 0.5-16
Glycerol 5-45
Anhydrous sodium sulfite 0.3
Distilled water 5-95 (4) gentamycin sulfate 0.5-16
Ethanol 5-30
Glycerol 5-40
Arlacel-85 0.1-5
Anhydrous sodium sulfite 0.3
Distilled water 10-95 (5) kanamycin sulfate 0.5-16
Glycerol 5-40
Distilled water 10-90
Anhydrous sodium sulfite 0.3
Oleum menthae 0.005-0.01 (6) kanamycin sulfate 0.5-16
Anhydrous sodium sulfite 0.3
Distilled water 5-95
Ethanol 5-20
Glycerol 5-50 (7) Micronomicin Sulfate 0.5-16
Glycerol 1-40
Anhydrous sodium sulfite 0.3
Distilled water 5-90 (8) Vistamycin 0.5-16
Anhydrous sodium sulfite 0.3
Glycerol 5-50
Distilled water 5-95 (9) sisomicin sulfate 0.5-16
Anhydrous sodium sulfite 0.3
Glycerol 0-50
Distilled water 5-90
Borneolum Syntheticum 1-1.5 (10) gentamycin sulfate 0.5-16
Anhydrous sodium sulfite 0.3
Glycerol 5-45
Distilled water 5-95
Borneolum Syntheticum 1-1.5
Oleum menthae 0.005-0.01 (11) sulphuric acid is liked big mycin 0.5-16
Anhydrous sodium sulfite 0.3
Glycerol 5-45
Distilled water 5-95
Borneolum Syntheticum 1-1.5
Oleum menthae 0.005-0.01 (12) sulphuric acid is liked big mycin 0.5-16
Anhydrous sodium sulfite 0.3
Glycerol 5-45
Distilled water 5-95
Oleum menthae 0.005-0.01
The preparation method of preparation of the present invention is: in keeping away the collarium border, dissolving mixings such as principal agent and solvent, adjuvant are made into concentrated solution earlier.Concentrated solution is sub-packed in (general 5-30 milliliter) in the proper container.Get final product behind the packaged micro-sprayer head.
Claims (10)
1, a kind of medicinal aerosol and compound method thereof, comprise antibiotics, solvent, auxiliary agent, antioxidant, flavoring agent and micro-sprayer, it is characterized in that antibiotics is Aminoglycoside antibiotics such as gentamycin sulfate, kanamycin sulfate, Micronomicin Sulfate, Vistamycin, Sissomicin, the big mycin of love; Solvent is a distilled water; Auxiliary agent is glycerol, ethylene glycol, ethanol, dimethyl sulfoxide and Arlacel-85 etc.; Antioxidant is anhydrous sodium sulfite, sodium pyrosulfate; Flavoring agent is Borneolum Syntheticum, Oleum menthae and other spices and essences; The weight percentage of each composition is antibiotics 0.5-20, and solvent 5-95, auxiliary agent are 1-50, flavoring agent 0.001-1.5.Antioxidant is 0.3.
2, method according to claim 1, the weight percentage that it is characterized in that each composition is gentamycin sulfate 0.5-16, ethylene glycol 5-50, distilled water 5-90.Anhydrous sodium sulfite 0.3
3, method according to claim 1, the weight percentage that it is characterized in that each composition is gentamycin sulfate 0.5-16, ethanol 10-45, distilled water 5-90, Oleum menthae 0.001-0.1, anhydrous sodium sulfite 0.3.
4, method according to claim 1, the weight percentage that it is characterized in that each composition is gentamycin sulfate 0.5-16, glycerol 5-45, distilled water 50-95, anhydrous sodium sulfite 0.3.
5, method according to claim 1, the weight percentage that it is characterized in that each composition is gentamycin sulfate 0.5-16, ethanol 5-30, glycerol 5-40, distilled water 50-95, anhydrous sodium sulfite 0.3.
6, method according to claim 1, the weight percentage that it is characterized in that each composition is kanamycin sulfate 0.5-20, glycerol 5-40, distilled water 10-90, Oleum menthae 0.005-0.01, anhydrous sodium sulfite 0.3.
7, method according to claim 1, the weight percentage that it is characterized in that each composition is for liking big mycin 0.5-16, glycerol 5-50, ethanol 5-20, distilled water 5-45, anhydrous sodium sulfite 0.3.
8, method according to claim 1, the weight percentage that it is characterized in that each composition is Micronomicin Sulfate 0.5-16, anhydrous sodium sulfite 0.3, glycerol 5-40, distilled water 5-95.
9, method according to claim 1, the weight percentage that it is characterized in that each composition is sisomicin sulfate 0.5-16, anhydrous sodium sulfite 0.3.Glycerol 5-40, distilled water 5-45.
10, method according to claim 1, the weight percentage that it is characterized in that each composition is Vistamycin 0.5-16, anhydrous sodium sulfite 0.3, glycerol 5-50, distilled water 5-95.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97106043 CN1209320A (en) | 1997-08-22 | 1997-08-22 | Medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97106043 CN1209320A (en) | 1997-08-22 | 1997-08-22 | Medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1209320A true CN1209320A (en) | 1999-03-03 |
Family
ID=5168320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97106043 Pending CN1209320A (en) | 1997-08-22 | 1997-08-22 | Medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1209320A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007068007A1 (en) * | 2005-12-07 | 2007-06-14 | Harm Benjamin Steyn | Use of a disinfectant for treating respiratory tract infections |
| CN101816669A (en) * | 2010-04-23 | 2010-09-01 | 广东药学院 | Composition containing gentamicin and borneol and use thereof |
| CN108904441A (en) * | 2018-07-26 | 2018-11-30 | 日照市牧邦畜牧科技有限公司 | A kind of stable neomycin sulphate solution and its preparation process |
| CN114177140A (en) * | 2021-12-10 | 2022-03-15 | 卓和药业集团股份有限公司 | Netilmicin sulfate aerosol |
-
1997
- 1997-08-22 CN CN 97106043 patent/CN1209320A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007068007A1 (en) * | 2005-12-07 | 2007-06-14 | Harm Benjamin Steyn | Use of a disinfectant for treating respiratory tract infections |
| CN101816669A (en) * | 2010-04-23 | 2010-09-01 | 广东药学院 | Composition containing gentamicin and borneol and use thereof |
| CN108904441A (en) * | 2018-07-26 | 2018-11-30 | 日照市牧邦畜牧科技有限公司 | A kind of stable neomycin sulphate solution and its preparation process |
| CN114177140A (en) * | 2021-12-10 | 2022-03-15 | 卓和药业集团股份有限公司 | Netilmicin sulfate aerosol |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007298814B2 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
| CN1191826C (en) | Pharmaceutical formulation | |
| US5080906A (en) | Method and composition for oral administration of n-acetylcysteine | |
| US20200345656A1 (en) | Cannabinoids compositions and methods | |
| US4789660A (en) | Insulin administration using methyl and propyl paraben | |
| CN1451388A (en) | Medicine for preventing and treating infectious diseases caused by virus, e.g. SARS | |
| HU206615B (en) | Process for producing hydrophyle, aqouos pumpspray composition containing nitroglycerol | |
| CN1197552C (en) | Preparations for the application of anti-inflammatory agents | |
| CN1658844A (en) | Low dose liquid entecavir formulations and use | |
| CN1209320A (en) | Medicine | |
| AU2014247141B2 (en) | Lozenge for treating a sore throat, hoarseness, and associated dry cough and for treating inflammatory diseases of the oral cavity and of the pharynx | |
| FI95201B (en) | A method of preparing liquid pharmaceutical compositions for intranasal administration | |
| EP0416678A1 (en) | Topical compositions containing Defibrotide | |
| CN1069192C (en) | Aerosol preparation and preparation method thereof | |
| KR20110017433A (en) | Pharmaceutical formulation of ketorolac for intranasal administration | |
| CN110193078A (en) | One group of pharmaceutical composition and its carrier and dosage form for Cobratoxin intranasal administration | |
| JPS60149530A (en) | Pharmaceutical water-based preparation | |
| CN1717245A (en) | Medicinal composition | |
| CN1709273A (en) | Roxhthromycin soft capsule and its preparing method | |
| RU2192877C1 (en) | Treatment-and-prophylactic composition for balsam | |
| CN1080851A (en) | The reinforcing agent of somatostatin | |
| JPS61126034A (en) | Transnasal carcitonin agent containing aldose | |
| CN1224351A (en) | Pharmaceutical preparation contg. nimesulide for oral administration | |
| CN1305474C (en) | Nose cavity administering formulation of nalmefene | |
| CN1206989C (en) | Mixed snuff prepn. for reducing side effect of Apomorphinum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |